EP0338364A2 - Lead impedance scanning system for pacemakers - Google Patents

Lead impedance scanning system for pacemakers Download PDF

Info

Publication number
EP0338364A2
EP0338364A2 EP89106279A EP89106279A EP0338364A2 EP 0338364 A2 EP0338364 A2 EP 0338364A2 EP 89106279 A EP89106279 A EP 89106279A EP 89106279 A EP89106279 A EP 89106279A EP 0338364 A2 EP0338364 A2 EP 0338364A2
Authority
EP
European Patent Office
Prior art keywords
lead
impedance
stimulation pulse
counter
impedance measurements
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP89106279A
Other languages
German (de)
French (fr)
Other versions
EP0338364B1 (en
EP0338364A3 (en
Inventor
Christer Dipl.-Ing. Ekwall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacesetter AB
Original Assignee
Siemens AG
Pacesetter AB
Siemens Elema AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22671826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0338364(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Siemens AG, Pacesetter AB, Siemens Elema AB filed Critical Siemens AG
Publication of EP0338364A2 publication Critical patent/EP0338364A2/en
Publication of EP0338364A3 publication Critical patent/EP0338364A3/en
Application granted granted Critical
Publication of EP0338364B1 publication Critical patent/EP0338364B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R27/00Arrangements for measuring resistance, reactance, impedance, or electric characteristics derived therefrom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/37Monitoring; Protecting
    • A61N1/3706Pacemaker parameters

Definitions

  • This invention relates to body implantable systems for electrical stimulation of physiologic function and, more particularly, to electronic circuitry associated with pacemakers for monitoring implanted pacemaker operation and providing indications of detected departures from standard levels of selected parameters.
  • cardiac pacemakers The technology of cardiac pacemakers has developed to a high level of sophistication of system performance.
  • the current generation of cardiac pacemakers incorporate microprocessors and related circuitry to sense and stimulate heart activity under a variety of physiological conditions. These pacemakers may be programmed to control the heart in correcting or compensating for various heart abnormalities which may be encountered in individual patients.
  • a detailed description of modern cardiac pacemaker technology is set forth in International Application Number PCT/US85/02010, entitled STIMULATED HEART INTERVAL MEASUREMENT, ADAPTIVE PACER AND METHOD OF OPERATION, assigned to the assignee hereof. The disclosure of that application is incorporated herein by reference.
  • AV synchrony relates to the sequential timing relationship that exists between the contractions of the atria and the ventricles. In a given heart cycle or beat, these contractions are typically manifest or measure by sensing electrical signals or waves that are attendant with the depolarization of heart tissue, which depolarizaton immediately precedes (and for most purposes can be considered concurrent with) the contraction of the cardiac tissue.
  • signals or waves can be viewed on an electrocardiogram and include a P-wave, representing the depolarizaton of the atria; the QRS wave (sometimes referred to as an R-wave, the predominant wave of the group), representing the depolarization of the ventricles; and the T-wave, representing the repolarization of the ventricles.
  • a P-wave representing the depolarizaton of the atria
  • the QRS wave sometimes referred to as an R-wave, the predominant wave of the group
  • the T-wave representing the repolarization of the ventricles.
  • SA node sinoatrial node
  • This specialized structure is located in the upper portion of the right atrium wall.
  • the SA node depolarizes spontaneously at an intrinsic rate of a little better than once each second (typically about 72 beats per minute).
  • the rate of depolarizaton and, therefore, the heart rate are influenced by various physical factors, which may produce tachycardia or bradycardia depending upon the particular patient condition.
  • the atrium contracts and forces the blood that has accumulated therein into the ventricle.
  • a short time later (a time sufficient to allow the bulk of the blood in the atrium to flow through the one-way valve into the ventricle), the ventricle contracts, forcing the blood out of the ventricle to body tissue.
  • a typical time interval between contraction of the atrium and contraction of the ventricle might be 60 ms; a typical time interval between contraction of the ventricle and the next contraction of the atrium might be 800 ms.
  • Atrial contraction A
  • V ventricle contraction
  • next atrial contraction A
  • the heart functions very efficiently as a pump in delivering life--sustaining blood to body tissue; where AV synchrony is absent, the heart functions as an inefficient pump (largely because the ventricle is contracting when it is not filled with blood).
  • a demand-type pacemaker is one that provides a stimulation pulse only when the heart fails to produce a natural depolarization on its own within a prescribed escape interval. In a dual chamber pacemaker, this is realized by placing electrodes in both the right atrium and right ventricle of the heart. These electrodes are coupled through intravenous and/or epicardial leads to sense amplifiers housed in an implanted pacemaker. Electrical activity occurring in these chambers can thus be sensed. When electrical activity is sensed, the pacemaker assumes that a depolarizaton or contraction of the indicated chamber has occurred.
  • a pulse generator also housed within the pacemaker housing, generates a stimulation pulse that is delivered to the indicated chamber, usually via the same lead or electrode as is used for sensing.
  • This stimulation pulse causes or forces the desired depolarization and contraction of the indicated chamber to occur.
  • the heart will either beat on its own (without stimulation from the pacemaker) at a rate that is at least just slightly faster than the stimulation rate defined by the escape interval, or the heart will be stimulated by the pacer at a rate controlled by the escape interval.
  • the stimulation rate provided by the pacemaker is typically referred to as the "programmed rate.”
  • Pacemakers have come to be classified according to type and functional mode of operation. For several years, a three-letter code has been used to describe the various types of pacemakers. In accordance with this code, the letter in the first position has been used to indicate the chamber being paced. Thus, V represents the ventricle, A represents the atrium, and D indicates that both the atrium and the ventricle are being paced. The letter in the second position for this code indicates the chamber being sensed. As with the chamber being paced, V, A and D when in the second position of the code indicate the chamber being sensed is the ventricle, the atrium or both the atrium and ventricle, respectively. In addition, O represents the lack of sensing.
  • the letter in the third position in this three-letter code signifies the mode of response of the pacemaker.
  • T represents triggered response
  • I represents inhibited response
  • D represents double response (atrial triggered and ventricle inhibited or atrial triggered/inhibited and ventricle inhibited).
  • O indicates none and R indicates reversed (where the pacemaker is activated by a fast heart rate but does not respond to a slow heart rate--in other words, a specialized antiarrhythmic pacemaker).
  • pacemakers include a sensor circuit that looks for electrical signals from spontaneous heart activity. On detection of such activity, the pacemaker stimulation action is modified, depending upon the functional mode or type of pacemaker. For example, in the VVI mode (ventricle paced and sensed, response inhibited mode), sensing of heart activity under certain time restrictions is interpreted as normal heart activity such that the stimulating action is inhibited.
  • VVI mode cardiac paced and sensed, response inhibited mode
  • One asserted pacemaker function analyzer for automatic evaluation and indication of the quality of performance of cardiac pacing systems is the subject of United States patent 4,527,567 of Fischler et al.
  • the analyzer of that patent is said to provide a comprehensive examination of asynchronous, demand and demand-hysteresis pacemakers of all makes, including the state of the pacemaker's battery, the intactness of the electronic circuitry and of the electrodes, and the proper location of the electrodes in the heart.
  • the manner in which this analysis is performed by the circuitry of that patent is entirely different from the operation of the lead impedance scanning system of the present invention.
  • lead impedance and “lead resistance” as used herein are not to be limited with reference to specific electrical circuit leads only. Rather, these terms as used are intended to encompass impedance of a complete circuit pate, including body tissue and fluids and any interface effects which may be presented, for example, by the connection between an electrode tip and heart tissue.
  • arrangements in accordance with the present invention comprise electrical circuitry for monitoring signals transmitted via the pacemaker system leads and noting excessive variations in measured impedance.
  • the monitoring provides a measurement of lead impedance with the occurrence of every heart stimulation pulse.
  • voltage level on a storage capacitor which is the source of heart stimulation pulses is sampled both before and after a stimulation pulse.
  • the difference in voltage level between two such samples due to the partial discharge of the storage capacitor resulting from the delivery of the stimulation pulse, is used to determine the instantaneous lead impedance which is a function of this voltage difference.
  • the derived value is compared with a moving average of stored lead impedance measurements and an error counter is incremented if the current value differs from the moving average by a predetermined amount.
  • the output form the circuit of the pacemaker which is provided for sensing heart activity is used to monitor changes in sensed signals which may related to problems with leads involved in sensing.
  • any detected abnormality in the sensing lead results in the incrementing of a second error counter.
  • the lead failure in this case is indicated as abnormal (unphysiological) sensed signal slew rates.
  • a lead fracture will momentarily provide step voltages or transient pulses with existing normal potentials between the body and conducting materials.
  • the count levels stored in the first and second error counters may be transferred to an appropriate test readout in order that attention may be directed to the fact that a possible lead problem exists.
  • FIG. 1 depicts the use of two bipolar leads 12 and 14, each being directed into a separate chamber of the right heart.
  • a bipolar lead comprises a single filar that includes two electrically insulated conductors.
  • the lead 14 includes a first conductor 16 that is electrically connected to a distal tip 18 of the lead. This distal tip is typically placed in a cavity of the right atrium 19 referred to as the atrial appendage 20.
  • a known distance from the distal tip 18 an electrode ring 22 is electrically connected to the other conductor 24 of the bipolar lead 14.
  • a distal tip 26 and a conductive ring 28 are associated with the bipolar lead 12 that is placed in the apex of the right ventricle 30.
  • the manner in which the leads 12 and 14 are inserted into the heart, as well as the manner in which the pacemaker 10 is implanted in the body of a patient, are well known in the art.
  • Fig. 1 may be considered to represent a rate-responsive pacer operating in the VVI mode if the bipolar lead 14 with its associated distal tip 18 and electrode ring 22 is eliminated from the figure so that only the bipolar lead 12 is left with its tip and ring 26, 28 inserted in the right ventricle 30, as shown in Fig. 1.
  • FIG. 2 A block diagram of a circuit in accordance with the present invention is shown in Fig. 2.
  • the circuit 40 is shown comprising a stimulation timing circuit 42 which contains the normal pacemaker timing and logic circuitry.
  • the circuit 40 is coupled to control the actuation of a switch S1 upon the occurrence of a stimulation signal STIM.
  • the source of the pacing output at terminal 46 is a capacitor C1 which is coupled to be charged by a charging circuit 44 and which delivers the pacing pulse to the output 46 through a series capacitor C4 when the switch S1 is closed.
  • Resistor R2 is provided to complete the circuit to capacitor C4 when switch S1 is open.
  • a sampling stage 50 is coupled to sample capacitor C1 before and after delivery of the packing pulse.
  • the stimulating impedance discriminator 54 maintains a moving average of lead impedance measurements according to Equation (1) and compares each new measurement with that average. If the measurement of lead impedance differs from the moving average by a predetermined value, an associated counter 56 is incremented to count the event as the occurrence of an error.
  • a polarity detector 55 is shown connected to the stimulating impedance discriminator 54 to provide an indication for the readout logic stage 70 of the direction of change for any differences in measurement of lead impedance which are detected by the stimulating impedance discriminator 54.
  • the polarity detector 55 provides an output indication of whether detected changes in lead impedance measurements involve an increase or decrease in impedance. This corresponds to an indication that lead degradation is in the direction of an open circuit (corresponding to measured increases in lead impedance) or in the direction of a short circuit (corresponding to a measured reduction in lead impedance).
  • a sensing detector 60 is coupled to the terminal 46 to respond to sensed heart activity.
  • the output of the sensing detector 60 is applied to a sensing impedance discriminator 62 which receives a delayed signal DS from a monostable delay circuit 64 that is triggered by the STIM output of the stimulation timing circuit 42. This serves to prevent indication of high slew rate signals from stimulation output origin.
  • the output of the sensing impedance discriminator 62 is applied to a second counter 66.
  • the sensing impedance discriminator 62 responds to the slope (slew) of the signal from the sensing detector 60 such that when a rate of change greater than 10 volts per second is detected, the count in the counter 66 is incremented.
  • a second polarity detector 63 is shown coupled to the sensing impedance discriminator 62 with an output being directed to the readout logic stage 70, in much the same fashion and for the same purpose as the polarity detector 55 which is connected to the stimulating impedance discriminator 54.
  • the detector 63 provides an output indication of increasing impedance where the slope of the signal from the sensing detector 60 is positive and an output indication of decreasing impedance where the slope of that signal is negative.
  • additional diagnostic information is provided at the readout logic stage 70 in response to polarity detectors 55, 63 over and above the mere indication of a detected change in lead impedance.
  • a readout logic stage 70 is coupled to the outputs of both counter stages 56 and 66 to provide an indication of the number of errors detected by the respective portions (stimulating signal and sensing signal) of the lead impedance analyzing circuit 40.
  • the inputs designated by the letter C indicate connections from the various stages to a system clock (not shown).
  • Fig. 3 represents the circuit 40 of Fig. 2 in more detailed schematic circuit form.
  • like elements have been given corresponding designations to those shown in Fig. 2.
  • the charging circuit 44 is represented as comprising a switch S2 and a capacitor C2, the latter having a small capacitance by comparison with C1.
  • C2 quickly assumes the voltage level of C1 without producing noticeable change therein.
  • the circuit of R1 and C3 serves to create a moving average of the voltage level of C1, since C3 has a much greater capacitance than C2.
  • Switches S3 and S4 are connected to provide alternating charge and discharge pulses to one input terminal of a first comparator stage 80 which is connected to receive at its other input the moving average of C1 voltage level.
  • the output of the comparator 80 is coupled to the first stage 82 of a three-bit shift register 88, having additional stages 84 and 86.
  • the outputs of the individual stage 82, 84, 86 are applied to three-terminal NAND gates 90, 92 while the outputs of the first stage 82 are additionally applied to two-input NAND gates 94, 96 which control switches S3 and S4.
  • the outputs of the NAND gates 90, 92 are applied to a further NAND gate 98, the output of which is applied to one input of AND gate 100.
  • An active output from gate 98 signifies the occurrence of an event corresponding to the detection of three successive errors or anomalous impedance measurements.
  • the output of AND gate 100 is coupled to a programmable down counter 102, which in turn is coupled to an up counter 104.
  • the programmable down counter 102 is connected to be set to a predetermined value delivered over the data bus 110, the latter being connected to receive the count in the up counter 104.
  • the monostable delay circuit 64 of Fig. 2 comprises a flip flop 120 coupled to receive the output of an NOR gate 122 and to provide an output through a buffer amplifier 124 to another NOR gate 126. This serves to provide a delayed signal DS following a stimulation pulse from the stimulation timing circuit 42 of Fig. 2 in phase with a clock signal.
  • the sensing portion of the circuit comprises a sense amplifier 130 coupled to receive heart signals for terminal 46 and apply them through a high pass filter 132 to one input of a second comparator stage 134, the other input of which is coupled to a voltage reference Vref.
  • the output of comparator stage 134 is applied to a flip flop 136, the output of which is applied, with the stimulation signal STIM, to an AND gate 138 which in turn is coupled to drive an up counter 140.
  • the counter 140 is connected to provide data to the data bus 110.
  • the delayed DS signal is developed.
  • capacitor C2 is connected to capacitor C1 via switch S2, and the same voltage level is developed on both capacitors C1 and C2.
  • Alternation fo the switch S2 transfers charge samples in bucket and dipper fashion from capacitor C1 to capacitor C3 in the moving average circuit to provide a voltage at one input of the comparator 80.
  • the stimulation pulse activates switch S1 to provide a pacing signal at terminal 46 from the capacitor C1.
  • a momentary change of lead impedance in the lead connected to output terminal 46 creates a difference of potentials in capacitors C2 and C3 which is sensed by the comparator 80 and applied to the shift register 88 at input stage 82. If three consecutive deviation signals are applied to the shift register 88, gates 90, 92 and 98 are activated to develop a condition at the input to gate 100 signifying an event. This in phase with a clock pulse activates AND gate 100 to decrement the down counter 102. The counter 102 is set to a predetermined count value on receipt of a STIM signal. When the voltage difference between capacitor C2 and capacitor C3 exceeds a certain threshold value, the output of gate 98 is active long enough to develop the output from the programmable down counter 102, thereby incrementing the up counter 104.
  • a rapidly changing input signal to the sense amplifier 130 produces a voltage level at the comparator 134 which is higher than Vref.
  • the signal form the comparator 134 sets the flip flop 136 if the DS signal is low.
  • the next stimulating pulse from the stage 42 (Fig. 2) will increment the second counter 140.
  • the two counters 104 and 140 are read via the data bus 110. From the numbers read out of the counters 104 and 140, determinations of system performance, relative to the impedance condition of the pacer leads may be made.
  • arrangements in accordance with the present invention monitor a prescribed pacemaker parameter related to the integrity of the implanted leads and keep a count according to the occurrences of a predetermined number of detected anomalies in succession.
  • An anomaly is determined to be a deviation from the norm for that parameter by some predetermined amount. What constitutes the norm is determined from the operation of the system over time. Isolated anomalies corresponding to a single occurrence are disregarded, but if the particular anomaly persists over three heart beats, the occurrence of the event is recorded in a counter. Thus, at some later tine, such as during a routing patient checkup, for example, the contents of the counter may be noted so that a decision may be made with respect to whether or not the possible problem corresponding to the noted events needs to be corrected.
  • the preferred embodiment of the invention advantageously provides two distinct related systems for noting anomalies with respect to the testing of lead impedance.
  • One system is based upon measurement of output energy delivered to the stimulation circuit during pacing; the other system involves the measurement of lead impedance from the monitoring of sensed heart signals.
  • An analysis of the count readouts in the independent counters of both systems may further enhance the process of determining the particular lead problem which is indicated, particularly from a correlation of the separate count readouts as in the case of a pacemaker system which uses the same lead for sensing and pacing.

Abstract

A pacemaker lead analyzer for measuring impedance during standard operation of an implanted pacemaker. The analyzer makes separate measurements of lead impedance during each heart signal and each pacing pulse. A moving average of measured parameters is maintained and recurring deviations from the norms are noted in separate event counters for subsequent analysis of the noted events as possible indications of impending failure of an implanted lead.

Description

  • This invention relates to body implantable systems for electrical stimulation of physiologic function and, more particularly, to electronic circuitry associated with pacemakers for monitoring implanted pacemaker operation and providing indications of detected departures from standard levels of selected parameters.
  • BACKGROUND OF THE INVENTION
  • The technology of cardiac pacemakers has developed to a high level of sophistication of system performance. The current generation of cardiac pacemakers incorporate microprocessors and related circuitry to sense and stimulate heart activity under a variety of physiological conditions. These pacemakers may be programmed to control the heart in correcting or compensating for various heart abnormalities which may be encountered in individual patients. A detailed description of modern cardiac pacemaker technology is set forth in International Application Number PCT/US85/02010, entitled STIMULATED HEART INTERVAL MEASUREMENT, ADAPTIVE PACER AND METHOD OF OPERATION, assigned to the assignee hereof. The disclosure of that application is incorporated herein by reference.
  • In order to efficiently perform its function as a pump, the heart must maintain a natural AV synchrony. The term "AV synchrony" relates to the sequential timing relationship that exists between the contractions of the atria and the ventricles. In a given heart cycle or beat, these contractions are typically manifest or measure by sensing electrical signals or waves that are attendant with the depolarization of heart tissue, which depolarizaton immediately precedes (and for most purposes can be considered concurrent with) the contraction of the cardiac tissue. These signals or waves can be viewed on an electrocardiogram and include a P-wave, representing the depolarizaton of the atria; the QRS wave (sometimes referred to as an R-wave, the predominant wave of the group), representing the depolarization of the ventricles; and the T-wave, representing the repolarization of the ventricles. (It is noted that the atria also are repolarized, but this atrial repolarization occurs at approximately the same time as the depolarization of the ventricles; and any electrical signal generated by atrial repolarization is generally minute and is masked out by the much larger QRS-wave on the electrocardiogram.)
  • Thus, it is the P-QRS-T cycle of waves that represents the natural AV synchrony of the heart. These waves, including the time relationships that exist therebetween, are carefully studied and monitored through conventional ECG techniques whenever the operation of the heart is being examined.
  • Initiation of the cardiac cycle normally begins with depolarization of the sinoatrial (SA) node. This specialized structure is located in the upper portion of the right atrium wall. The SA node depolarizes spontaneously at an intrinsic rate of a little better than once each second (typically about 72 beats per minute). The rate of depolarizaton and, therefore, the heart rate are influenced by various physical factors, which may produce tachycardia or bradycardia depending upon the particular patient condition.
  • Optimally, in a normal cardiac cycle and in response to the initiating SA depolarization, the atrium contracts and forces the blood that has accumulated therein into the ventricle. A short time later (a time sufficient to allow the bulk of the blood in the atrium to flow through the one-way valve into the ventricle), the ventricle contracts, forcing the blood out of the ventricle to body tissue. A typical time interval between contraction of the atrium and contraction of the ventricle might be 60 ms; a typical time interval between contraction of the ventricle and the next contraction of the atrium might be 800 ms. Thus, it is an atrial contraction (A), followed a relatively short time thereafter by a ventricle contraction (V), followed a relatively long time thereafter by the next atrial contraction, that produces the desired AV synchrony. Where AV synchrony exists, the heart functions very efficiently as a pump in delivering life--sustaining blood to body tissue; where AV synchrony is absent, the heart functions as an inefficient pump (largely because the ventricle is contracting when it is not filled with blood).
  • Multiple-mode, demand-type, cardiac pacemakers are designed, insofar as is possible, to maintain an AV synchrony for damaged or diseased hearts that are unable to do so on their own. A demand-type pacemaker is one that provides a stimulation pulse only when the heart fails to produce a natural depolarization on its own within a prescribed escape interval. In a dual chamber pacemaker, this is realized by placing electrodes in both the right atrium and right ventricle of the heart. These electrodes are coupled through intravenous and/or epicardial leads to sense amplifiers housed in an implanted pacemaker. Electrical activity occurring in these chambers can thus be sensed. When electrical activity is sensed, the pacemaker assumes that a depolarizaton or contraction of the indicated chamber has occurred. If no electrical activity is sensed within a prescribed time interval, typically referred to as an atrial or ventricular escape interval, then a pulse generator, also housed within the pacemaker housing, generates a stimulation pulse that is delivered to the indicated chamber, usually via the same lead or electrode as is used for sensing. This stimulation pulse causes or forces the desired depolarization and contraction of the indicated chamber to occur. Hence, by first sensing whether a natural depolarization occurs in each chamber, and by second stimulating at controlled time intervals each chamber with an external stimulation pulse in the absence of a natural depolarization, the AV synchrony of the heart can be maintained. Thus, with a demand pacer, the heart will either beat on its own (without stimulation from the pacemaker) at a rate that is at least just slightly faster than the stimulation rate defined by the escape interval, or the heart will be stimulated by the pacer at a rate controlled by the escape interval. The stimulation rate provided by the pacemaker is typically referred to as the "programmed rate."
  • Pacemakers have come to be classified according to type and functional mode of operation. For several years, a three-letter code has been used to describe the various types of pacemakers. In accordance with this code, the letter in the first position has been used to indicate the chamber being paced. Thus, V represents the ventricle, A represents the atrium, and D indicates that both the atrium and the ventricle are being paced. The letter in the second position for this code indicates the chamber being sensed. As with the chamber being paced, V, A and D when in the second position of the code indicate the chamber being sensed is the ventricle, the atrium or both the atrium and ventricle, respectively. In addition, O represents the lack of sensing. The letter in the third position in this three-letter code signifies the mode of response of the pacemaker. In this position, T represents triggered response, I represents inhibited response, D represents double response (atrial triggered and ventricle inhibited or atrial triggered/inhibited and ventricle inhibited). O indicates none and R indicates reversed (where the pacemaker is activated by a fast heart rate but does not respond to a slow heart rate--in other words, a specialized antiarrhythmic pacemaker).
  • As noted, most pacemakers include a sensor circuit that looks for electrical signals from spontaneous heart activity. On detection of such activity, the pacemaker stimulation action is modified, depending upon the functional mode or type of pacemaker. For example, in the VVI mode (ventricle paced and sensed, response inhibited mode), sensing of heart activity under certain time restrictions is interpreted as normal heart activity such that the stimulating action is inhibited.
  • The discussion thus far has followed the assumption that a pacemaker and its associated circuitry operate without malfunction. By the very nature of man-made devices, such is not always the case. Whereas electronic circuitry can be, and is, incorporated within the pacemaker itself for exercising or testing various circuit components, the status of battery power sources, and the effectiveness of various amplifiers, waveform shaping stages and the like, it is often more difficult to test the integrity of the leads and implanted electrodes to which the pacemaker is coupled for pacing operation.
  • At the implanting of the pacemaker and electrode system, minor damage is sometimes incurred which may affect the system's electrical insulation. This type of damage may go undetected and be without present effect on the implanted system, but the condition may manifest itself after extended time in service. When a breakdown or significant degradation of the pacemaker lead insulation occurs, it can have serious or even disastrous results, depending upon whether or not the breakdown is of a catastrophic nature. Various types of lead damage may produce different types of failure or degradation. For example, an isolation defect on the stimulaton electrode shunts the energy intended for the heart to some other point. A lead breakage can in some environmental situations temporarily or permanently reduce the stimulation output, sometimes drastically. Another type of detectable error relates to the failure of the electrode tip to be in proper contact with the heart wall.
  • While the lead defects which have been mentioned thus far are more in the nature of catastrophic failures, there may also occur failures or degradation of a less drastic nature which may be intermittent of which may build up over time. In a common situation, errors often start as temporary or intermittent errors. These can be virtually impossible to discover with commonly used techniques. It is not permissible to test on a random or periodic basis for lead faults in the manner in which power lines or telephone lines, for example, may be tested as, for example, by applying an over-voltage to a suspected circuit, simply because the breakdown of insulation in pacemaker leads under such condition may produce catastrophic results in the patient. It would be desirable to be able to use the signals encountered in the normal operation of an implanted pacemaker in the process analysis to determine impending failure or serious degradation from the temporary or intermittent errors which may be detected. A system for performing such a function would be expected to monitor standard heart operation and to use detected deviations or departures from signal norm to indicate the occurrence of such.
  • There may be various approaches to the regular monitoring of heart signals for the detection of abnormalities, some of which may relate to the circuitry employed in the implanted pacemaker system. One asserted pacemaker function analyzer for automatic evaluation and indication of the quality of performance of cardiac pacing systems is the subject of United States patent 4,527,567 of Fischler et al. The analyzer of that patent is said to provide a comprehensive examination of asynchronous, demand and demand-hysteresis pacemakers of all makes, including the state of the pacemaker's battery, the intactness of the electronic circuitry and of the electrodes, and the proper location of the electrodes in the heart. The manner in which this analysis is performed by the circuitry of that patent is entirely different from the operation of the lead impedance scanning system of the present invention.
  • PREFERRED EMBODIMENTS
  • Although the embodiments of the invention disclosed herein are shown and described in the context of a cardiac pacemaker, it should be understood that the invention is not limited thereto. The principles of the present invention may find application in connection with specific devices which are implanted for the purpose of providing electrical stimulation of other physiologic functions or of living animal tissue in general.
  • It should also be understood that the terms "lead impedance" and "lead resistance" as used herein are not to be limited with reference to specific electrical circuit leads only. Rather, these terms as used are intended to encompass impedance of a complete circuit pate, including body tissue and fluids and any interface effects which may be presented, for example, by the connection between an electrode tip and heart tissue.
  • SUMMARY OF THE INVENTION
  • In brief, arrangements in accordance with the present invention comprise electrical circuitry for monitoring signals transmitted via the pacemaker system leads and noting excessive variations in measured impedance. The monitoring provides a measurement of lead impedance with the occurrence of every heart stimulation pulse. Thus, not only are permanent lead abnormalities, such as insulation breakdown, lead breaks and the like, detected by arrangements in accordance with the present invention, but so also are lead impedance anomalies of a temporary or intermittent nature as well as significant but gradual variations in lead impedance which may be symptomatic of impending lead failure.
  • In one particular arrangement in accordance with the present invention, voltage level on a storage capacitor which is the source of heart stimulation pulses is sampled both before and after a stimulation pulse. The difference in voltage level between two such samples, due to the partial discharge of the storage capacitor resulting from the delivery of the stimulation pulse, is used to determine the instantaneous lead impedance which is a function of this voltage difference. The derived value is compared with a moving average of stored lead impedance measurements and an error counter is incremented if the current value differs from the moving average by a predetermined amount. Similarly, the output form the circuit of the pacemaker which is provided for sensing heart activity is used to monitor changes in sensed signals which may related to problems with leads involved in sensing. Any detected abnormality in the sensing lead results in the incrementing of a second error counter. The lead failure in this case is indicated as abnormal (unphysiological) sensed signal slew rates. For example, a lead fracture will momentarily provide step voltages or transient pulses with existing normal potentials between the body and conducting materials.
  • During a patient checkup, the count levels stored in the first and second error counters may be transferred to an appropriate test readout in order that attention may be directed to the fact that a possible lead problem exists.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The above and other objects, features and advantages of the present invention will be more apparent from the following more particular description thereof presented in conjunction with the accompanying drawings, wherein:
    • Fig. 1 is a schematic representation of a dual chamber cardiac pacemaker shown implanted in association with a heart for pacing;
    • Fig. 2 is a schematic block diagram of one particular arrangement in accordance with the invention for incorporation in a pacemaker like that shown in Fig. 1; and
    • Fig. 3 is a schematic circuit diagram showing further details of the arrangement of Fig. 2.
    DETAILED DESCRIPTION OF THE INVENTION
  • The following description is of the best presently contemplated mode of carrying out the invention. This description is not to be taken in a limiting sense but is made for the purpose of describing the general principles of the invention. The scope of the invention should be determined with reference to the appended claims.
  • Referring now to Fig. 1, there is shown a simplified representation of one way that an implanted pacemaker 10 may make electrical contact with the heart. Fig. 1 depicts the use of two bipolar leads 12 and 14, each being directed into a separate chamber of the right heart. A bipolar lead comprises a single filar that includes two electrically insulated conductors. For example, the lead 14 includes a first conductor 16 that is electrically connected to a distal tip 18 of the lead. This distal tip is typically placed in a cavity of the right atrium 19 referred to as the atrial appendage 20. A known distance from the distal tip 18 an electrode ring 22 is electrically connected to the other conductor 24 of the bipolar lead 14. Similarly, a distal tip 26 and a conductive ring 28 are associated with the bipolar lead 12 that is placed in the apex of the right ventricle 30. The manner in which the leads 12 and 14 are inserted into the heart, as well as the manner in which the pacemaker 10 is implanted in the body of a patient, are well known in the art.
  • The diagram of Fig. 1 may be considered to represent a rate-responsive pacer operating in the VVI mode if the bipolar lead 14 with its associated distal tip 18 and electrode ring 22 is eliminated from the figure so that only the bipolar lead 12 is left with its tip and ring 26, 28 inserted in the right ventricle 30, as shown in Fig. 1.
  • A block diagram of a circuit in accordance with the present invention is shown in Fig. 2. The circuit 40 is shown comprising a stimulation timing circuit 42 which contains the normal pacemaker timing and logic circuitry. The circuit 40 is coupled to control the actuation of a switch S1 upon the occurrence of a stimulation signal STIM. The source of the pacing output at terminal 46 is a capacitor C1 which is coupled to be charged by a charging circuit 44 and which delivers the pacing pulse to the output 46 through a series capacitor C4 when the switch S1 is closed. Resistor R2 is provided to complete the circuit to capacitor C4 when switch S1 is open.
  • A sampling stage 50 is coupled to sample capacitor C1 before and after delivery of the packing pulse. Sampled voltages from the sampling stage 50 are delivered to an analog-to-digital (A/D) converter 52, the output of which in digital form is applied to a stimulating impedance discriminator 54 which contains the circuitry for evaluating changes in lead impedance as a function of the voltage difference between the two levels sampled before and after delivery of a stimulation pulse corresponding to the following equation:
    R = -Tp/Cl 1n(1-dV/Vo))      (1)
    where R represents a lead impedance,
    Tp is the stimulation pulse duration,
    Cl is the source capacitor for the stimulation pulse,
    Vo is the source voltage, and
    dV is the voltage difference between the two sampled values.
  • This equation is derived from the well-­known relation with respect to time (t) for the voltage (v) across a discharging capacitor with initial voltage (Vo):
    v = Vo exp(-t/RC)      (2)
  • The stimulating impedance discriminator 54 maintains a moving average of lead impedance measurements according to Equation (1) and compares each new measurement with that average. If the measurement of lead impedance differs from the moving average by a predetermined value, an associated counter 56 is incremented to count the event as the occurrence of an error.
  • A polarity detector 55 is shown connected to the stimulating impedance discriminator 54 to provide an indication for the readout logic stage 70 of the direction of change for any differences in measurement of lead impedance which are detected by the stimulating impedance discriminator 54. Thus, for example, the polarity detector 55 provides an output indication of whether detected changes in lead impedance measurements involve an increase or decrease in impedance. This corresponds to an indication that lead degradation is in the direction of an open circuit (corresponding to measured increases in lead impedance) or in the direction of a short circuit (corresponding to a measured reduction in lead impedance).
  • A sensing detector 60 is coupled to the terminal 46 to respond to sensed heart activity. The output of the sensing detector 60 is applied to a sensing impedance discriminator 62 which receives a delayed signal DS from a monostable delay circuit 64 that is triggered by the STIM output of the stimulation timing circuit 42. This serves to prevent indication of high slew rate signals from stimulation output origin. The output of the sensing impedance discriminator 62 is applied to a second counter 66. The sensing impedance discriminator 62 responds to the slope (slew) of the signal from the sensing detector 60 such that when a rate of change greater than 10 volts per second is detected, the count in the counter 66 is incremented. A second polarity detector 63 is shown coupled to the sensing impedance discriminator 62 with an output being directed to the readout logic stage 70, in much the same fashion and for the same purpose as the polarity detector 55 which is connected to the stimulating impedance discriminator 54. The detector 63 provides an output indication of increasing impedance where the slope of the signal from the sensing detector 60 is positive and an output indication of decreasing impedance where the slope of that signal is negative. Thus, additional diagnostic information is provided at the readout logic stage 70 in response to polarity detectors 55, 63 over and above the mere indication of a detected change in lead impedance.
  • A readout logic stage 70 is coupled to the outputs of both counter stages 56 and 66 to provide an indication of the number of errors detected by the respective portions (stimulating signal and sensing signal) of the lead impedance analyzing circuit 40. The inputs designated by the letter C indicate connections from the various stages to a system clock (not shown).
  • Fig. 3 represents the circuit 40 of Fig. 2 in more detailed schematic circuit form. In this figure, like elements have been given corresponding designations to those shown in Fig. 2.
  • In Fig. 3, the charging circuit 44 is represented as comprising a switch S2 and a capacitor C2, the latter having a small capacitance by comparison with C1. Thus, when capacitor C2 is connected to capacitor C1, as indicated with the condition of switch S2 shown in Fig. 3, C2 quickly assumes the voltage level of C1 without producing noticeable change therein. The circuit of R1 and C3 serves to create a moving average of the voltage level of C1, since C3 has a much greater capacitance than C2. Switches S3 and S4 are connected to provide alternating charge and discharge pulses to one input terminal of a first comparator stage 80 which is connected to receive at its other input the moving average of C1 voltage level. The output of the comparator 80 is coupled to the first stage 82 of a three-bit shift register 88, having additional stages 84 and 86. The outputs of the individual stage 82, 84, 86 are applied to three-terminal NAND gates 90, 92 while the outputs of the first stage 82 are additionally applied to two-input NAND gates 94, 96 which control switches S3 and S4. The outputs of the NAND gates 90, 92 are applied to a further NAND gate 98, the output of which is applied to one input of AND gate 100. An active output from gate 98 signifies the occurrence of an event corresponding to the detection of three successive errors or anomalous impedance measurements. The output of AND gate 100 is coupled to a programmable down counter 102, which in turn is coupled to an up counter 104. The programmable down counter 102 is connected to be set to a predetermined value delivered over the data bus 110, the latter being connected to receive the count in the up counter 104.
  • The monostable delay circuit 64 of Fig. 2 comprises a flip flop 120 coupled to receive the output of an NOR gate 122 and to provide an output through a buffer amplifier 124 to another NOR gate 126. This serves to provide a delayed signal DS following a stimulation pulse from the stimulation timing circuit 42 of Fig. 2 in phase with a clock signal.
  • The sensing portion of the circuit comprises a sense amplifier 130 coupled to receive heart signals for terminal 46 and apply them through a high pass filter 132 to one input of a second comparator stage 134, the other input of which is coupled to a voltage reference Vref. The output of comparator stage 134 is applied to a flip flop 136, the output of which is applied, with the stimulation signal STIM, to an AND gate 138 which in turn is coupled to drive an up counter 140. The counter 140 is connected to provide data to the data bus 110.
  • In the operation of the circuit of Fig. 3, following a stimulating pulse from the stimulating timing circuit 42 (Fig.2), the delayed DS signal is developed. During this time, capacitor C2 is connected to capacitor C1 via switch S2, and the same voltage level is developed on both capacitors C1 and C2. Alternation fo the switch S2 transfers charge samples in bucket and dipper fashion from capacitor C1 to capacitor C3 in the moving average circuit to provide a voltage at one input of the comparator 80. As described in connection with Fig. 2, the stimulation pulse activates switch S1 to provide a pacing signal at terminal 46 from the capacitor C1. A momentary change of lead impedance in the lead connected to output terminal 46 creates a difference of potentials in capacitors C2 and C3 which is sensed by the comparator 80 and applied to the shift register 88 at input stage 82. If three consecutive deviation signals are applied to the shift register 88, gates 90, 92 and 98 are activated to develop a condition at the input to gate 100 signifying an event. This in phase with a clock pulse activates AND gate 100 to decrement the down counter 102. The counter 102 is set to a predetermined count value on receipt of a STIM signal. When the voltage difference between capacitor C2 and capacitor C3 exceeds a certain threshold value, the output of gate 98 is active long enough to develop the output from the programmable down counter 102, thereby incrementing the up counter 104.
  • A rapidly changing input signal to the sense amplifier 130 produces a voltage level at the comparator 134 which is higher than Vref. As a result, the signal form the comparator 134 sets the flip flop 136 if the DS signal is low. When this occurs at least once during a stimulating pulse interval, the next stimulating pulse from the stage 42 (Fig. 2) will increment the second counter 140. At pacemaker follow-up, the two counters 104 and 140 are read via the data bus 110. From the numbers read out of the counters 104 and 140, determinations of system performance, relative to the impedance condition of the pacer leads may be made.
  • As shown and described hereinabove, arrangements in accordance with the present invention monitor a prescribed pacemaker parameter related to the integrity of the implanted leads and keep a count according to the occurrences of a predetermined number of detected anomalies in succession. An anomaly is determined to be a deviation from the norm for that parameter by some predetermined amount. What constitutes the norm is determined from the operation of the system over time. Isolated anomalies corresponding to a single occurrence are disregarded, but if the particular anomaly persists over three heart beats, the occurrence of the event is recorded in a counter. Thus, at some later tine, such as during a routing patient checkup, for example, the contents of the counter may be noted so that a decision may be made with respect to whether or not the possible problem corresponding to the noted events needs to be corrected.
  • The preferred embodiment of the invention advantageously provides two distinct related systems for noting anomalies with respect to the testing of lead impedance. One system is based upon measurement of output energy delivered to the stimulation circuit during pacing; the other system involves the measurement of lead impedance from the monitoring of sensed heart signals. An analysis of the count readouts in the independent counters of both systems may further enhance the process of determining the particular lead problem which is indicated, particularly from a correlation of the separate count readouts as in the case of a pacemaker system which uses the same lead for sensing and pacing.
  • Although there have been described above specific arrangements of a lead impedance scanning system for pacemakers in accordance with the invention for the purpose of illustrating the manner in which the invention may be used to advantage, it will be appreciated that the invention is not limited thereto. Accordingly, any and all modifications, variations or equivalent arrangements which may occur to those skilled in the art should be considered to be within the scope of the invention as defined in the annexed claims.
  • Bezugszeichenliste
    • 10 pacemaker
    • 12,14 leads
    • 16 conductor
    • 18,26 distal tip
    • 19 right atrium
    • 20 atrial appendage
    • 22 electrode ring
    • 24 conductor
    • 22,28 ring
    • 30 ventricle
    • 40,42,44 circuit
    • 46 terminal
    • 46 output
    • 52 converter
    • 54,62 discriminator
    • 55,63 polarity detector
    • 56,66 counter stages
    • 64 delay circuit
    • 60 sensing detector
    • 70 logic stage
    • 80 comparator
    • 82,84,86 stage
    • 88 register
    • 90,92,94,96,98 NAND gate
    • 100 AND gate
    • 102,104 counter
    • 110 data bus
    • 120,136 flip flop
    • 122,126 NOR gate
    • 124 buffer amplifier
    • 130 sense amplifier
    • 132 filter
    • 134 comparator stage
    • 140 counter
    • C1,C2,C3,C4 capacitor
    • R1,C3 circuit
    • R2 resistor
    • S1,S2,S3,S4 switch

Claims (33)

1. A lead impedance scanning system for an implantable stimulation device comprising:
means for making lead impedance measurements during operation of the device;
means for comparing said impedance measurements with a preselected reference; and
means responsive to the detection of measurement deviations which deviate from said reference by a predetermined amount for indicating the occurrence of a change in lead impedance.
2. The system of claim 1 wherein the device is a pacemaker and the means for making lead impedance measurements comprise means for measuring the energy delivered to a pacing lead during a stimulation pulse.
3. The system of claim 2 wherein said last-­mentioned means include sampling means for sampling the energy level of the source of stimulation pulses before and after delivery of a stimulation pulse.
4. The system of claim 3 wherein sample voltages from the sampling means are used to provide a measurement of impedance in accordance with the following equations:
R = -Tp/Cl 1n(1-dV/Vo))
where R respresents lead impedance,
Tp is the stimulation pulse duration,
Cl is the storage capacitor source for the stimulation pulse,
Vo is the source voltage, and
dV is the voltage difference between two voltage samples taken before and after delivery of a stimulation pulse.
5. The system of claim 3 further including means for developing a moving average of impedance measurements as said preselected reference for comparison with individual impedance measurements.
6. The system of claim 5 further including counter means for counting events corresponding to measurement deviations for subsequent analysis as an indication of a possibly defective lead, and means for advancing the counter means under predetermined conditions related to said measurement deviations.
7. The system of claim 6 wherein the means for advancing the counter means include means for establishing a counter advancing signal only upon the occurrence of a predetermined number of said measurement deviations in succession.
8. The system of claim 7 wherein said last-­mentioned means comprises a three-bit shift register for developing a counter advancing signal only upon the occurrence of three measurement deviations in succession.
9. The system of claim 5 further including means for detecting the direction of change of impedance relative to said reference and for providing an indication of said detected direction of change of impedance.
10. The system of claim 1 wherein the means for making lead impedance measurements include means for measuring lead impedance from detected heart signals.
11. The system of claim 10 wherein the means for making lead impedance measurements further include means for developing signals corresponding to the slope of detected heart signal waveforms.
12. The system of claim 11 further including counter means for counting events corresponding to measurement deviations for subsequent analysis as an indication of a possibly defective lead, and means for advancing the counter means under predetermined conditions related to said measurement deviations.
13. The system of claim 11 wherein the comparing means comprise means for comparing said slope signals with a selected voltage reference and advancing the counter means only when a slope signal exceeds said voltage reference.
14. The system of claim 13 further including means for indicating the polarity of said slope signals to show the direction of change of impedance.
15. The system of claim 1 wherein the means for making lead impedance measurements include means for measuring impedance during the application of a stimulation pulse and means for measuring impedance from detected heart signals.
16. The system of claim 15 wherein the comparing means comprise a first comparator for comparing lead impedance measurements derived from energy delivered to the pacing lead during a stimulation pulse with a first reference corresponding to a moving average of such lead impedance measurements and a second comparator for comparing the slope of signal waveforms derived from sensed heart signals with a second predetermined voltage reference.
17. The system of claim 16 wherein the counter means comprise a first counter for storing a count corresponding to the occurrence of a predetermined number of said measurement deviations in succession which are derived from measurements made during the delivery of a stimulation pulse and a second counter for storing a count corresponding to the detection of rates of change of sensed heart signals in excess of a predetermined reference level.
18. A method of discovering defective leads of an implantable stimulation device comprising the steps of:
making lead impedance measurements during operation of the device;
comparing said impedance measurements with a preselected reference; and
noting the occurrence of measurement deviations which deviate from said reference by a predetermined amount.
19. The method of claim 18 further including the step of establishing a count of groups of measurement deviations for subsequent analysis as an indication of a defective lead; wherein a group is defined under predetermined conditions related to said measurement deviations.
20. The method of claim 18 further including the steps of detecting the polarity of said measurement deviations relative to said reference and providing an indication of direction of change of impedance.
21. The method of claim 18 wherein the step of making lead impedance measurements comprises measuring the energy delivered to a pacing lead of a pacemaker during a stimulation pulse.
22. The method of claim 21 wherein the energy measuring step includes sampling the source of stimulation pulses before and after delivery of a stimulation pulse.
23. The method of claim 22 wherein samples from the sampling step are used to provide a measurement of impedance in accordance with the following equation:
R = -Tp/Cl 1n(1-dV/Vo))
where R represent a lead impedance,
Tp is the stimulation pulse duration,
Cl is the storage capacitor source for stimulation pulse,
Vo is the source voltage, and
dV is the voltage difference between two voltage samples taken before and after delivery of a stimulation pulse.
24. The method of claim 22 further including the step of developing a moving average of impedance measurements as said preselected reference for comparison with individual impedance measurements.
25. The method of claim 24 wherein a group is defined as a predetermined number of said measurement deviations in succession.
26. The method of claim 25 wherein said group comprises three measurement deviations in succession.
27. The method of claim 18 wherein the step of making lead impedance measurements includes measuring lead impedance from detected heart signals.
28. The method of claim 27 wherein the step of making lead impedance measurements further includes developing signals corresponding to the slope of detected heart signal waveforms.
29. The method of claim 28 wherein the step of comparing comprises comparing said slope signals with a selected voltage reference and counting a measurement deviation only when a slope signal exceeds said voltage reference.
30. The method of claim 19 wherein the step of making lead impedance measurements includes both measuring impedance during the application of a stimulation pulse and measuring impedance from detected heart signals.
31. The method of claim 30 wherein the step of comparing comprises both comparing lead impedance measurements derived from energy delivered to the lead during a stimulation pulse with a first reference corresponding to a moving average of such lead impedance measurements and comparing the slope of signal waveforms derived from sensed heart signals with a second predetermined voltage reference.
32. The method of claim 31 further including the step of providing an indication of the direction of change of lead impedance concurrently with providing an indication of impedance measurement deviations.
33. The method of claim 31 further including storing a count in a first counter corresponding to the occurrence of a predetermined number of said measurement deviations in succession which are derived from measurements made during the delivery of a stimulation pulse and storing a count in a second counter corresponding to the detection of rates of change of sensed heart signals in excess of a predetermined reference level.
EP89106279A 1988-04-19 1989-04-10 Lead impedance scanning system for pacemakers Expired - Lifetime EP0338364B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US183191 1988-04-19
US07/183,191 US4899750A (en) 1988-04-19 1988-04-19 Lead impedance scanning system for pacemakers

Publications (3)

Publication Number Publication Date
EP0338364A2 true EP0338364A2 (en) 1989-10-25
EP0338364A3 EP0338364A3 (en) 1990-08-29
EP0338364B1 EP0338364B1 (en) 1994-07-27

Family

ID=22671826

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89106279A Expired - Lifetime EP0338364B1 (en) 1988-04-19 1989-04-10 Lead impedance scanning system for pacemakers

Country Status (5)

Country Link
US (1) US4899750A (en)
EP (1) EP0338364B1 (en)
JP (1) JPH01313065A (en)
AU (1) AU604456B2 (en)
DE (1) DE68916998T2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534018A (en) * 1994-11-30 1996-07-09 Medtronic, Inc. Automatic lead recognition for implantable medical device
WO1997036647A1 (en) * 1996-04-03 1997-10-09 Medtronic, Inc. Egm recording system for implantable medical device
EP0813890A2 (en) * 1996-06-20 1997-12-29 Pacesetter AB Medical apparatus
WO1998042406A1 (en) * 1997-03-26 1998-10-01 Intermedics Inc. Cardiac stimulator with lead failure detector and warning system
WO1999024112A1 (en) * 1997-11-07 1999-05-20 Medtronic, Inc. Non-physiologic sense detection for implantable medical devices
WO1999024113A1 (en) * 1997-11-07 1999-05-20 Medtronic, Inc. Pacing lead impedance monitoring circuit and method
US7031773B1 (en) 2003-01-10 2006-04-18 Pacesetter, Inc. Implantable cardiac stimulation system providing autocapture and lead impedance assessment and method

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137021A (en) * 1990-11-29 1992-08-11 Medtronic, Inc. Lead current measurement circuit
US5174286A (en) * 1990-12-07 1992-12-29 Raul Chirife Sensor for right ventricular and thoracic volumes using the trailing edge value of a generated pulse
US5197479A (en) * 1991-05-13 1993-03-30 Mortara Instrument Automatic electrode channel impedance measurement system for egg monitor
AU665543B2 (en) * 1991-06-28 1996-01-11 Liquip Sales Pty Limited A system/apparatus for indicating electrical continuity of fluid carrying components
US5201865A (en) * 1991-10-28 1993-04-13 Medtronic, Inc. Medical lead impedance measurement system
US5224475A (en) * 1991-11-20 1993-07-06 Medtronic, Inc. Method and apparatus for termination of ventricular tachycardia and ventricular fibrillation
US7189208B1 (en) * 1992-09-23 2007-03-13 Endocardial Solutions, Inc. Method for measuring heart electrophysiology
US6240307B1 (en) 1993-09-23 2001-05-29 Endocardial Solutions, Inc. Endocardial mapping system
US7930012B2 (en) * 1992-09-23 2011-04-19 St. Jude Medical, Atrial Fibrillation Division, Inc. Chamber location method
CA2144973C (en) * 1992-09-23 2010-02-09 Graydon Ernest Beatty Endocardial mapping system
US5297549A (en) * 1992-09-23 1994-03-29 Endocardial Therapeutics, Inc. Endocardial mapping system
SE9300283D0 (en) * 1993-01-29 1993-01-29 Siemens Elema Ab PROCEDURE AND DEVICE FOR ELECTRODOOD MONITORING BY ELECTRICAL HEART STIMULATORS
US5350401A (en) * 1993-03-26 1994-09-27 Siemens Pacesetter, Inc. Implantable cardioverter/defibrillator device having means for determining and treating low amplitude ventricular fibrillation and method thereof
US5391199A (en) * 1993-07-20 1995-02-21 Biosense, Inc. Apparatus and method for treating cardiac arrhythmias
US5738096A (en) * 1993-07-20 1998-04-14 Biosense, Inc. Cardiac electromechanics
US5431692A (en) * 1993-08-02 1995-07-11 Telectronics Pacing Systems, Inc. Method and apparatus for testing compatibility of lead polarity and polarity programming of a cardiac stimulator
US5454377A (en) * 1993-10-08 1995-10-03 The Ohio State University Method for measuring the myocardial electrical impedance spectrum
US5713367A (en) * 1994-01-26 1998-02-03 Cambridge Heart, Inc. Measuring and assessing cardiac electrical stability
US5507786A (en) * 1994-04-14 1996-04-16 Pacesetter, Inc. System and method for measuring and storing parametric data pertaining to operating characteristics of an implantable medical device
US5713933A (en) * 1994-11-30 1998-02-03 Medtronic, Inc. Method and apparatus for automatic pacing threshold determination
US5549646A (en) * 1994-12-06 1996-08-27 Pacesetter, Inc. Periodic electrical lead intergrity testing system and method for implantable cardiac stimulating devices
US5817022A (en) * 1995-03-28 1998-10-06 Sonometrics Corporation System for displaying a 2-D ultrasound image within a 3-D viewing environment
US6246898B1 (en) 1995-03-28 2001-06-12 Sonometrics Corporation Method for carrying out a medical procedure using a three-dimensional tracking and imaging system
US5795298A (en) * 1995-03-28 1998-08-18 Sonometrics Corporation System for sharing electrocardiogram electrodes and transducers
US5797849A (en) * 1995-03-28 1998-08-25 Sonometrics Corporation Method for carrying out a medical procedure using a three-dimensional tracking and imaging system
US5868673A (en) * 1995-03-28 1999-02-09 Sonometrics Corporation System for carrying out surgery, biopsy and ablation of a tumor or other physical anomaly
US5830144A (en) * 1995-03-28 1998-11-03 Vesely; Ivan Tracking data sheath
US5620474A (en) * 1995-04-24 1997-04-15 Vitatron Medical, B.V. System and method for determining indicated pacemaker replacement time based upon battery impedance measurement
US5718241A (en) * 1995-06-07 1998-02-17 Biosense, Inc. Apparatus and method for treating cardiac arrhythmias with no discrete target
US5954665A (en) * 1995-06-07 1999-09-21 Biosense, Inc. Cardiac ablation catheter using correlation measure
DE69628906T2 (en) * 1995-09-29 2004-05-19 Medtronic, Inc., Minneapolis ADAPTABLE SEARCH OF AV DELAY
US5837900A (en) * 1996-06-21 1998-11-17 Medtronic Inc System and method for detecting metal ion oxidation in pacing lead
US5741311A (en) * 1996-06-27 1998-04-21 Medtronic, Inc. Implantable medical device system with method for determining lead condition
US5722997A (en) * 1996-09-17 1998-03-03 Sulzer Intermedics Inc. Method and apparatus for cardiac impedance sensing
US5755742A (en) * 1996-11-05 1998-05-26 Medtronic, Inc. Cardioversion/defibrillation lead impedance measurement system
US6019725A (en) * 1997-03-07 2000-02-01 Sonometrics Corporation Three-dimensional tracking and imaging system
US6490474B1 (en) * 1997-08-01 2002-12-03 Cardiac Pathways Corporation System and method for electrode localization using ultrasound
US5891179A (en) * 1997-11-20 1999-04-06 Paceseter, Inc. Method and apparatus for monitoring and displaying lead impedance in real-time for an implantable medical device
US6022322A (en) 1998-02-06 2000-02-08 Intermedics Inc. Non-invasive cardiorespiratory monitor with synchronized bioimpedance sensing
US6141585A (en) * 1998-05-08 2000-10-31 Intermedics Inc. Implantable cardiac stimulator with electrode-tissue interface characterization
CA2292526A1 (en) * 1998-06-03 1999-12-09 Neurocontrol Corporation Percutaneous intramuscular stimulation system
US7806829B2 (en) 1998-06-30 2010-10-05 St. Jude Medical, Atrial Fibrillation Division, Inc. System and method for navigating an ultrasound catheter to image a beating heart
US7263397B2 (en) 1998-06-30 2007-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and apparatus for catheter navigation and location and mapping in the heart
US7670297B1 (en) 1998-06-30 2010-03-02 St. Jude Medical, Atrial Fibrillation Division, Inc. Chamber mapping system
US6950689B1 (en) 1998-08-03 2005-09-27 Boston Scientific Scimed, Inc. Dynamically alterable three-dimensional graphical model of a body region
US5944746A (en) * 1998-10-30 1999-08-31 Pacesetter, Inc. ICD with continuous regular testing of defibrillation lead status
US6721600B2 (en) 2000-01-19 2004-04-13 Medtronic, Inc. Implantable lead functional status monitor and method
US6317633B1 (en) 1999-01-19 2001-11-13 Medtronic, Inc. Implantable lead functional status monitor and method
US6370432B1 (en) * 1999-08-20 2002-04-09 Cardiac Pacemakers, Inc. Pacemaker passive measurement testing system and method
US6445952B1 (en) 2000-05-18 2002-09-03 Medtronic, Inc. Apparatus and method for detecting micro-dislodgment of a pacing lead
US6687538B1 (en) * 2000-06-19 2004-02-03 Medtronic, Inc. Trial neuro stimulator with lead diagnostics
WO2002018009A1 (en) 2000-08-26 2002-03-07 Medtronic, Inc. Implantable lead functional status monitor and method
US6658294B1 (en) 2001-08-29 2003-12-02 Pacesetter, Inc. Implantable cardiac device having an impedance monitoring circuit and method
FR2831743B1 (en) * 2001-10-25 2004-01-30 Cit Alcatel IS-IS FAULT TOLERANT ROUTING SYSTEM AND CORRESPONDING METHOD
US6695790B2 (en) 2001-10-26 2004-02-24 Medtronic, Inc. Method and system for determining kidney failure
US20030199938A1 (en) * 2002-04-22 2003-10-23 Karel Smits Precise cardiac lead placement based on impedance measurements
US7047083B2 (en) * 2002-09-30 2006-05-16 Medtronic, Inc. Method and apparatus for identifying lead-related conditions using lead impedance measurements
US20040088033A1 (en) * 2002-10-31 2004-05-06 Smits Karel F.A.A. Implantable medical lead designs
US8010207B2 (en) 2002-10-31 2011-08-30 Medtronic, Inc. Implantable medical lead designs
US20050261571A1 (en) * 2004-05-21 2005-11-24 Willis Nathaniel P 3-D ultrasound navigation during radio-frequency ablation
US20060025828A1 (en) * 2004-07-28 2006-02-02 Armstrong Randolph K Impedance measurement for an implantable device
US7574259B1 (en) 2004-11-12 2009-08-11 Pacesetter, Inc. Capture threshold and lead condition analysis
US7308310B1 (en) 2005-01-26 2007-12-11 Pacesetter, Inc. Implantable cardiac stimulation device providing bipolar autocapture and lead impedance assessment and method
WO2006119103A2 (en) * 2005-04-29 2006-11-09 Medtronic, Inc. Event-based lead impedance monitoring
US7515961B2 (en) * 2005-04-29 2009-04-07 Medtronic, Inc. Method and apparatus for dynamically monitoring, detecting and diagnosing lead conditions
US7623919B2 (en) * 2005-04-29 2009-11-24 Medtronic, Inc. Distributed lead functionality testing
US7644714B2 (en) * 2005-05-27 2010-01-12 Apnex Medical, Inc. Devices and methods for treating sleep disorders
US7567840B2 (en) * 2005-10-28 2009-07-28 Cyberonics, Inc. Lead condition assessment for an implantable medical device
EP2335775B1 (en) * 2005-12-01 2018-02-07 Second Sight Medical Products, Inc. Fitting a neural prosthesis using impedance and electrode height
US7769455B2 (en) * 2006-01-27 2010-08-03 Cyberonics, Inc. Power supply monitoring for an implantable device
US8180462B2 (en) * 2006-04-18 2012-05-15 Cyberonics, Inc. Heat dissipation for a lead assembly
US7899535B2 (en) * 2006-06-16 2011-03-01 Cardiac Pacemakers, Inc. Automatic electrode integrity management systems and methods
US8478420B2 (en) * 2006-07-12 2013-07-02 Cyberonics, Inc. Implantable medical device charge balance assessment
US20080027524A1 (en) * 2006-07-26 2008-01-31 Maschino Steven E Multi-electrode assembly for an implantable medical device
ES2722849T3 (en) 2006-10-13 2019-08-19 Cyberonics Inc Devices and systems for the treatment of obstructive sleep apnea
US9913982B2 (en) 2011-01-28 2018-03-13 Cyberonics, Inc. Obstructive sleep apnea treatment devices, systems and methods
US9186511B2 (en) 2006-10-13 2015-11-17 Cyberonics, Inc. Obstructive sleep apnea treatment devices, systems and methods
US9744354B2 (en) 2008-12-31 2017-08-29 Cyberonics, Inc. Obstructive sleep apnea treatment devices, systems and methods
US8855771B2 (en) 2011-01-28 2014-10-07 Cyberonics, Inc. Screening devices and methods for obstructive sleep apnea therapy
US9205262B2 (en) 2011-05-12 2015-12-08 Cyberonics, Inc. Devices and methods for sleep apnea treatment
US7930028B2 (en) * 2006-10-20 2011-04-19 Biotronik Crm Patent Ag Implantable cardiac device with a shock lead
US7974707B2 (en) * 2007-01-26 2011-07-05 Cyberonics, Inc. Electrode assembly with fibers for a medical device
US8868203B2 (en) * 2007-10-26 2014-10-21 Cyberonics, Inc. Dynamic lead condition detection for an implantable medical device
US8942798B2 (en) * 2007-10-26 2015-01-27 Cyberonics, Inc. Alternative operation mode for an implantable medical device based upon lead condition
WO2009148426A1 (en) * 2008-06-02 2009-12-10 Medtronic, Inc. Sensing integrity determination based on cardiovascular pressure
US20090299421A1 (en) * 2008-06-02 2009-12-03 Medtronic, Inc. Evaluation of implantable medical device sensing integrity based on evoked signals
EP2237835A1 (en) * 2008-06-02 2010-10-13 Medtronic, Inc. Impedance variability analysis to identify lead-related conditions
WO2009148429A1 (en) * 2008-06-02 2009-12-10 Medtronic, Inc. Electrogram storage for suspected non-physiological episodes
US9037240B2 (en) * 2008-06-02 2015-05-19 Medtronic, Inc. Electrode lead integrity reports
US7974690B2 (en) * 2008-06-30 2011-07-05 Medtronic, Inc. Lead integrity testing during suspected tachyarrhythmias
US9522277B2 (en) 2008-07-28 2016-12-20 Medtronic, Inc. Lead integrity testing triggered by sensed signal saturation
US7953488B2 (en) * 2008-07-31 2011-05-31 Medtronic, Inc. Pre-qualification of an alternate sensing configuration
US8078277B2 (en) * 2008-10-29 2011-12-13 Medtronic, Inc. Identification and remediation of oversensed cardiac events using far-field electrograms
US10118042B2 (en) 2008-10-31 2018-11-06 Medtronic, Inc. Lead integrity testing triggered by sensed asystole
US8311639B2 (en) * 2009-07-08 2012-11-13 Nevro Corporation Systems and methods for adjusting electrical therapy based on impedance changes
EP2403589B1 (en) 2009-02-10 2014-01-22 Nevro Corporation Systems for delivering neural therapy correlated with patient status
US8406892B2 (en) * 2009-06-15 2013-03-26 Kallis Technical Services Method and apparatus for detecting imminent structural failure of an electrical lead in an implanted cardiac therapy medical device
US8498710B2 (en) 2009-07-28 2013-07-30 Nevro Corporation Linked area parameter adjustment for spinal cord stimulation and associated systems and methods
US20110098765A1 (en) * 2009-10-27 2011-04-28 Medtronic, Inc. Detecting lead related condition during delivery of therapeutic electrical signals
US8396543B2 (en) * 2010-01-28 2013-03-12 Medtronic, Inc. Storage of data for evaluation of lead integrity
US8478428B2 (en) 2010-04-23 2013-07-02 Cyberonics, Inc. Helical electrode for nerve stimulation
US8874229B2 (en) 2010-04-28 2014-10-28 Cyberonics, Inc. Delivering scheduled and unscheduled therapy without detriment to battery life or accuracy of longevity predictions
US8543206B2 (en) 2010-06-25 2013-09-24 Pacesetter, Inc. Early detection of lead failure using an impedance histogram
US8463384B2 (en) 2011-01-27 2013-06-11 Medtronic, Inc. Isolated lead conductor measurements for fault detection
US9539428B2 (en) 2011-01-27 2017-01-10 Medtronic, Inc. Isolating lead conductor for fault detection
US8577459B2 (en) 2011-01-28 2013-11-05 Cyberonics, Inc. System and method for estimating battery capacity
US8761884B2 (en) 2011-04-14 2014-06-24 Cyberonics, Inc. Device longevity prediction for a device having variable energy consumption
US8761885B2 (en) 2011-04-29 2014-06-24 Cyberonics, Inc. Battery life estimation based on voltage depletion rate
US8855765B2 (en) 2011-06-09 2014-10-07 Medtronic, Inc. Fault tolerant methods and architectures for embedded intelligence in medical leads
US8798751B2 (en) 2011-06-09 2014-08-05 Medtronic, Inc. Method and apparatus to manage lead-related conditions for fault tolerance enhancements
US8577457B2 (en) 2011-07-07 2013-11-05 Medtronics, Inc. Isolating lead body for fault detection
US8774909B2 (en) 2011-09-26 2014-07-08 Medtronic, Inc. Episode classifier algorithm
US8437840B2 (en) 2011-09-26 2013-05-07 Medtronic, Inc. Episode classifier algorithm
US9668668B2 (en) 2011-09-30 2017-06-06 Medtronic, Inc. Electrogram summary
US8744560B2 (en) 2011-09-30 2014-06-03 Medtronic, Inc. Electrogram summary
US8521281B2 (en) 2011-10-14 2013-08-27 Medtronic, Inc. Electrogram classification algorithm
US8886296B2 (en) 2011-10-14 2014-11-11 Medtronic, Inc. T-wave oversensing
US9232898B2 (en) 2011-10-27 2016-01-12 Medtronic, Inc. Method and apparatus to manage lead-related conditions for fault tolerance enhancements
US9956417B2 (en) 2012-05-08 2018-05-01 Medtronic, Inc. Identifying lead insulation breaches and externalization of lead conductors
US9295840B1 (en) 2013-01-22 2016-03-29 Nevro Corporation Systems and methods for automatically programming patient therapy devices
US9895538B1 (en) 2013-01-22 2018-02-20 Nevro Corp. Systems and methods for deploying patient therapy devices
US9731133B1 (en) 2013-01-22 2017-08-15 Nevro Corp. Systems and methods for systematically testing a plurality of therapy programs in patient therapy devices
WO2015053769A1 (en) 2013-10-09 2015-04-16 Advanced Bionics Ag Systems for measuring electrode impedance during a normal operation of a cochlear implant system
US9764139B2 (en) 2014-01-24 2017-09-19 Medtronic, Inc. Pre-implant detection
EP4241662A1 (en) 2014-02-11 2023-09-13 Cyberonics, Inc. Systems for detecting and treating obstructive sleep apnea
WO2015123483A1 (en) 2014-02-13 2015-08-20 Medtronic, Inc. Lead monitoring frequency based on lead and patient characteristics
US9517344B1 (en) 2015-03-13 2016-12-13 Nevro Corporation Systems and methods for selecting low-power, effective signal delivery parameters for an implanted pulse generator
US10300277B1 (en) 2015-12-14 2019-05-28 Nevro Corp. Variable amplitude signals for neurological therapy, and associated systems and methods
US11235165B2 (en) * 2019-02-04 2022-02-01 Pacesetter, Inc. Lead impedance monitoring for an implantable medical device
CN110193142A (en) * 2019-05-24 2019-09-03 深圳市先健心康医疗电子有限公司 Pacing lead dropping detection method and temporary cardiac pacemaker
WO2021137202A1 (en) * 2020-01-05 2021-07-08 Impulse Dynamics Nv Lead condition testing in an implanted cardiac device

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088139A (en) * 1976-03-08 1978-05-09 Medalert Corporation Automatic detection and registration of failure condition in a cardiac pacer monitoring system
FR2369836A1 (en) * 1976-11-03 1978-06-02 Medtronic Inc IMPLANTABLE STIMULATOR WITH ALARM DEVICE
GB2026870A (en) * 1978-07-20 1980-02-13 Medtronic Inc Body implantable pacemaker
US4476869A (en) * 1980-06-05 1984-10-16 Intermedics, Inc. Pacer analyzer
US4527567A (en) * 1980-04-01 1985-07-09 Yeda Research & Development Company, Ltd. Method and apparatus for automatically evaluating the quality of the performance of a cardiac pacing system
DE3536111A1 (en) * 1984-11-28 1986-05-22 Telectronics N.V., Curacao, Niederländische Antillen TEST IMPEDANCE FOR HEART PACTER BATTERIES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459995A (en) * 1979-03-08 1984-07-17 Lafayette R. Hubbard Indicating device for use in a device for measuring and indicating changes in resistance of a living body
US4380237A (en) * 1979-12-03 1983-04-19 Massachusetts General Hospital Apparatus for making cardiac output conductivity measurements
US4630615A (en) * 1984-05-21 1986-12-23 Cordis Corporation Apparatus for measuring impedance
FR2585557B1 (en) * 1985-08-02 1987-11-06 Centre Nat Rech Scient DEVICE FOR MEASURING ELECTRICAL CHARACTERISTICS OF LIVING TISSUES, AND PARTICULARLY TEMPERATURE FOR CAPACITIVE OR RADIATIVE HYPERTHERMIA
US4674518A (en) * 1985-09-06 1987-06-23 Cardiac Pacemakers, Inc. Method and apparatus for measuring ventricular volume
US4697591A (en) * 1986-06-16 1987-10-06 Siemens Aktiengesellschaft Cardiac pacer for pacing a human heart and pacing method
AU625593B2 (en) * 1987-06-30 1992-07-16 Ventracor Limited Combined pacemaker parameter and vital sign monitor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088139A (en) * 1976-03-08 1978-05-09 Medalert Corporation Automatic detection and registration of failure condition in a cardiac pacer monitoring system
FR2369836A1 (en) * 1976-11-03 1978-06-02 Medtronic Inc IMPLANTABLE STIMULATOR WITH ALARM DEVICE
GB2026870A (en) * 1978-07-20 1980-02-13 Medtronic Inc Body implantable pacemaker
US4527567A (en) * 1980-04-01 1985-07-09 Yeda Research & Development Company, Ltd. Method and apparatus for automatically evaluating the quality of the performance of a cardiac pacing system
US4476869A (en) * 1980-06-05 1984-10-16 Intermedics, Inc. Pacer analyzer
DE3536111A1 (en) * 1984-11-28 1986-05-22 Telectronics N.V., Curacao, Niederländische Antillen TEST IMPEDANCE FOR HEART PACTER BATTERIES

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534018A (en) * 1994-11-30 1996-07-09 Medtronic, Inc. Automatic lead recognition for implantable medical device
WO1997036647A1 (en) * 1996-04-03 1997-10-09 Medtronic, Inc. Egm recording system for implantable medical device
EP0813890A2 (en) * 1996-06-20 1997-12-29 Pacesetter AB Medical apparatus
EP0813890A3 (en) * 1996-06-20 1998-12-16 Pacesetter AB Medical apparatus
WO1998042406A1 (en) * 1997-03-26 1998-10-01 Intermedics Inc. Cardiac stimulator with lead failure detector and warning system
WO1999024112A1 (en) * 1997-11-07 1999-05-20 Medtronic, Inc. Non-physiologic sense detection for implantable medical devices
WO1999024113A1 (en) * 1997-11-07 1999-05-20 Medtronic, Inc. Pacing lead impedance monitoring circuit and method
US7031773B1 (en) 2003-01-10 2006-04-18 Pacesetter, Inc. Implantable cardiac stimulation system providing autocapture and lead impedance assessment and method

Also Published As

Publication number Publication date
EP0338364B1 (en) 1994-07-27
DE68916998D1 (en) 1994-09-01
EP0338364A3 (en) 1990-08-29
DE68916998T2 (en) 1995-03-23
AU3314289A (en) 1989-10-26
US4899750A (en) 1990-02-13
JPH01313065A (en) 1989-12-18
AU604456B2 (en) 1990-12-13

Similar Documents

Publication Publication Date Title
EP0338364B1 (en) Lead impedance scanning system for pacemakers
US5003975A (en) Automatic electrode configuration of an implantable pacemaker
US5201865A (en) Medical lead impedance measurement system
US5741311A (en) Implantable medical device system with method for determining lead condition
US7047083B2 (en) Method and apparatus for identifying lead-related conditions using lead impedance measurements
EP0341297B1 (en) Sensing margin detectors for implantable electromedical devices
US5391192A (en) Automatic ventricular pacing pulse threshold determination utilizing an external programmer and a surface electrocardiogram
US5476486A (en) Automatic atrial pacing pulse threshold determination utilizing an external programmer and a V-sense electrode
US5458623A (en) Automatic atrial pacing threshold determination utilizing an external programmer and a surface electrogram
US5361776A (en) Time domain reflectometer impedance sensor method of use and implantable cardiac stimulator using same
US10118042B2 (en) Lead integrity testing triggered by sensed asystole
EP0338363B1 (en) Configuration programming of an implantable pacemaker
US20120109235A1 (en) Capture detection in response to lead related conditions
EP1525028B1 (en) Apparatus for shock lead impedance measurement
AU4687093A (en) Compressed storage of data in cardiac pacemakers
EP0944413A1 (en) Cardioversion/defibrillation lead impedance measurement system
US20040073266A1 (en) Automatic detection of defibrillation lead
US4505276A (en) Device for detecting retrograde conduction
US7317943B2 (en) Capture threshold monitoring
EP0786268A1 (en) Heart stimulator with verification of atrial capture
Green et al. Detection of faults in implanted cardiac pacemakers.
Frick Efficiency of a pacemaker clinic to prevent sudden pacing failures.
WO1992019319A1 (en) Apparatus and method for an implanted cardiac pacemaker with multiuse electrode with potential restoration
Rydén et al. FUNCTIONAL CHECKING OF IMPLANTED CARDIAC PACEMAKERS: Methods, Values Indicative of Impending Pacemaker Failure, and Results of Testing of Fixed Rate, Ventricular Synchronous and A trial Synchronous Pacemakers
Edgar et al. Development and preliminary clinical tests of an impedance sensing VDD recording pacemaker for diagnosis and research

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): DE FR GB IT NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): DE FR GB IT NL SE

17P Request for examination filed

Effective date: 19901220

17Q First examination report despatched

Effective date: 19930719

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE FR GB IT NL SE

REF Corresponds to:

Ref document number: 68916998

Country of ref document: DE

Date of ref document: 19940901

ITF It: translation for a ep patent filed

Owner name: STUDIO JAUMANN

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19941027

ET Fr: translation filed
ITPR It: changes in ownership of a european patent

Owner name: CESSIONE;PACESETTER AB

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: BIOTRONIK MESS- UND THERAPIEGERAETE GMBH & CO ING

Effective date: 19950427

NLS Nl: assignments of ep-patents

Owner name: PACESETTER AB

NLR1 Nl: opposition has been filed with the epo

Opponent name: BIOTRONIK MESS- UND THERAPIEGERAETE GMBH & CO INGE

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: PACESETTER AB

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: PACESETTER AB

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLBO Opposition rejected

Free format text: ORIGINAL CODE: EPIDOS REJO

APAC Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPO

APAE Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOS REFNO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19980320

Year of fee payment: 10

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: PACESETTER AB

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: PACESETTER AB

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990410

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19990410

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: ST. JUDE MEDICAL AB

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: BIOTRONIK MESS- UND THERAPIEGERAETE GMBH & CO INGE

Effective date: 19950427

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: ST. JUDE MEDICAL AB

R26 Opposition filed (corrected)

Opponent name: BIOTRONIK MESS- UND THERAPIEGERAETE GMBH & CO INGE

Effective date: 19950427

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20010322

Year of fee payment: 13

NLR1 Nl: opposition has been filed with the epo

Opponent name: BIOTRONIK MESS- UND THERAPIEGERAETE GMBH & CO

APAC Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPO

PLBN Opposition rejected

Free format text: ORIGINAL CODE: 0009273

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: OPPOSITION REJECTED

27O Opposition rejected

Effective date: 20010509

NLR2 Nl: decision of opposition
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021101

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20021101

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20060331

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20060424

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060430

Year of fee payment: 18

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070410